Introducing the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
Listening carefully to our physician partners, we have applied our spirit of innovation to the complexities of endovascular repair.

Controlled.
Conformable.
Predictable.
Now, endovascular repair of aneurysms, transections and Type B dissections can be carried out with greater precision than ever.

The GORE® ACTIVE CONTROL System is a new delivery system that offers controlled, staged deployment. Accurate device positioning pre-deployment

Staged deployment enables placement and angulation refinement without alteration of blood pressure

Optional angulation control at both intermediate and full diameter

Reduced profiles on 10 device sizes, with no changes to the stent graft itself

Now, endovascular repair of aneurysms, transections and Type B dissections can be carried out with greater precision than ever.

The GORE® ACTIVE CONTROL System enhances the exceptional conformability of the stent graft, facilitating the optimized wall apposition.

Controlled. Conformable. Predictable.

The GORE® ACTIVE CONTROL System is a new delivery system that offers controlled, staged deployment.

Purpose-built to deliver new levels of control.

- Accurate device positioning pre-deployment
- Staged deployment enables placement and angulation refinement without alteration of blood pressure
- Optional angulation control at both intermediate and full diameter
- Reduced profiles on 10 device sizes, with no changes to the stent graft itself

Through five-year follow-up* (N = 217)

- Procedural survival 100%
- Spinal cord ischemia 3.7%
- Fracture 0%
- 30-day survival 91.4%
- Renal failure 0.5%
- Compression 0%
- Freedom from device-related reintervention 93.1%
- Aortic rupture associated with treated area 1.8%
- Migration 0%

* Reported outcomes following 5-year follow-up in FDA IDE clinical studies.

Proven results in complex procedures.

Built on the established success of the Conformable GORE® TAG® Device.

Through five-year follow-up* (N = 217)

- Procedural survival 100%
- Spinal cord ischemia 3.7%
- Fracture 0%
- 30-day survival 91.4%
- Renal failure 0.5%
- Compression 0%
- Freedom from device-related reintervention 93.1%
- Aortic rupture associated with treated area 1.8%
- Migration 0%

* Reported outcomes following 5-year follow-up in FDA IDE clinical studies.
We lead the way in TEVAR innovation.

- The first thoracic stent graft approved in Europe, U.S. and Japan*
- The first TEVAR device to reach 100,000 devices distributed
- The first device approved for endovascular treatment of aneurysms, transections and Type B dissections
- The first to feature a new delivery system that offers controlled, staged deployment
- Twenty years of TEVAR experience

* Conformable GORE® TAG® Device

Learn more at goremedical.com/active-control

INDICATIONS FOR USE IN THE U.S.: The GORE® TAG® Conformable Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac / femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac / femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to Instructions for Use at goremedical.com for a complete description of all warnings, precautions, and adverse events.

INDICATIONS FOR USE UNDER CE MARK: The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of the descending thoracic aorta. CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to Instructions for Use at goremedical.com for a complete description of all warnings, precautions, and adverse events. Rx Only

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)
goremedical.com

Products listed may not be available in all markets.

GORE, ACTIVE CONTROL, TAG and designs are trademarks of W. L. Gore & Associates.
AY1112-EN1 AUGUST 2019